Prc2 inhibitors
AssigneeMirati Therapeutics, Inc.
InventorsMatthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
Claims30
A method for treating cancer in a patient, wherein the cancer is a polycomb repressive complex 2 (PRC2)-associated cancer, comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A method for inhibiting polycomb repressive complex 2 (PRC2) in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.